Literature DB >> 2973783

Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta.

M Bihari-Varga1, E Gruber, M Rotheneder, R Zechner, G M Kostner.   

Abstract

The lipoprotein complexing activity of glycosaminoglycans (GAG) prepared from human aortas with lipoprotein Lp(a) in comparison to low density lipoproteins (LDL) was determined tubidimetrically in the presence of Ca++. In control experiments, purified chondroitin-6 sulfate and proteoglycans (PG) were used. Lp(a) exhibited approximately a threefold higher reactivity. Analyzing the chemical composition of the complexes, we found that Lp(a) had greater than fourfold higher binding capacity for GAG. The binding capacity of Lp(a) to PG was 3.4-fold higher as compared to LDL. The binding capacity of both lipoproteins for chondroitin-6 sulfate was only 50% in comparison to GAG, but again Lp(a) was four times more reactive. Neuraminidase treatment of LDL or Lp(a) did not interfere with GAG or chondroitin-6 sulfate binding. If, on the other hand, Lp(a) was treated with dithiothreitol and the Lp(a)-specific protein (apoprotein [apo] a) was removed, the GAG binding was reduced by about 45%. Apo a by itself gave no insoluble complexes with GAG. LDL and Lp(a)-s GAG and -LP(a)-PG complexes were incubated with mouse peritoneal macrophages (MPM), and the stimulation of cholesteryl ester formation was studied. At identical lipoprotein cholesterol concentrations, Lp(a)-GAG complexes exhibited a 1.3-fold higher stimulation of cholesterol esterification as compared to LDL-GAG. This difference was even more striking if lipoproteins were compared at a molar basis. PG-lipoprotein complexes were much more active with respect to interactions with MPM. The highest amount of cholesterol ester formation upon incubation with MPM was found with PG-Lp(a) complexes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973783     DOI: 10.1161/01.atv.8.6.851

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  16 in total

1.  Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix.

Authors:  S Pillarisetti; L Paka; J C Obunike; L Berglund; I J Goldberg
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 2.  Lipoprotein (a): a historical appraisal.

Authors:  Karam M Kostner; Gert M Kostner
Journal:  J Lipid Res       Date:  2016-11-07       Impact factor: 5.922

3.  Enhanced macrophage uptake of lipoprotein(a) after Ca2+-induced aggregate-formation.

Authors:  S Tanaka; A Yashiro; H Tasaki; Y Nakashima
Journal:  Lipids       Date:  1998-04       Impact factor: 1.880

Review 4.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

Review 5.  The response-to-retention hypothesis of early atherogenesis.

Authors:  K J Williams; I Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

6.  Lp(a) and the risk of coronary heart disease.

Authors:  M Bihari-Varga; G Kostner; A Czinner
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

7.  Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus.

Authors:  A Császár; H Dieplinger; C Sandholzer; I Karádi; E Juhász; H Drexel; T Halmos; L Romics; J R Patsch; G Utermann
Journal:  Diabetologia       Date:  1993-01       Impact factor: 10.122

8.  Immunohistochemical distribution of lipoprotein epitopes in xanthomata from patients with familial hypercholesterolemia.

Authors:  N Sugiyama; S Marcovina; A M Gown; H Seftel; B Joffe; A Chait
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

Review 9.  Lipoprotein(a): new insights into an atherogenic lipoprotein.

Authors:  W Bartens; C Wanner
Journal:  Clin Investig       Date:  1994-08

10.  Lipoprotein (a) concentrations as risk indicators for atherosclerosis.

Authors:  G M Kostner; A Czinner; K H Pfeiffer; M Bihari-Varga
Journal:  Arch Dis Child       Date:  1991-09       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.